A medical food product to address common underlying genetic metabolic imbalances and improve retinal blood flow. Retinal ischemia is preceded by endothelial dysfunction and often with elevated homocysteine (Hcy). By addressing these underlying metabolic abnormalities which lowers Hcy, Ocufolin™ has been shown to increase both retinal and conjunctival tissue perfusion.
New Clinical Data
In 2020, two new clinical studies using Ocufolin™ were conducted and published by the Bascom Palmer Eye Institute (U of Miami). The trial results matched and extended original clinical observations leading to the formulation of Ocufolin™.
We are Global Healthcare Focus
Our mission is to serve the eye care industry with peer reviewed clinical data and innovative insights for improving the care of retinal ischemia and retinal endothelial injury. This focus has guided our work for more than a decade and culminates in the launch of Ocufolin™. This product is the embodiment of our best practices, our best science and manufacturing processes. We trust that it will serve the needs of your patients as it has for ours. We look forward to speaking with you.
How to Order
Wholesale: As a medical food, Ocufolin is meant for distribution through physicians/healthcare professionals. Please create an account and once we verify you as a wholesaler, you can purchase products.
Retail: As a medical food, Ocufolin is meant for distribution through physicians/healthcare professionals. However, a patient may buy the product directly from GHF by creating an account and if their physician reviews the product, agrees to supervise the patient's use and signs off on the Patient Request Form. These extra steps are required to demonstrate appropriate physician supervision to the FDA.
Please contact us for distribution details.